April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
The Effect of Valproic Acid in Mouse Models of RP
Author Affiliations & Notes
  • S. Kaushal
    Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts
  • S. M. Noorwez
    Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts
  • R. Tzekov
    Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts
  • D. Huang
    Bascom Palmer Eye Institute, University of Miami, Miami, Florida
  • Y. Li
    Bascom Palmer Eye Institute, University of Miami, Miami, Florida
  • R. Wen
    Bascom Palmer Eye Institute, University of Miami, Miami, Florida
  • Footnotes
    Commercial Relationships  S. Kaushal, None; S.M. Noorwez, None; R. Tzekov, None; D. Huang, None; Y. Li, None; R. Wen, None.
  • Footnotes
    Support  Retina Research and Education Fund, NIH grant EY-018586, JEK grant 08KN-09, Hope for Vision, Foundation Fighting Blindness, NIH center grant P30-EY014801, and Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3735. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Kaushal, S. M. Noorwez, R. Tzekov, D. Huang, Y. Li, R. Wen; The Effect of Valproic Acid in Mouse Models of RP. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3735.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the effect of valproic acid (VPA) on the amounts of folded rhodopsin in a P23H mouse model and assess VPA’s neuroprotective effect in the S334ter-3 rat model.

Methods: : Heterozygous P23H opsin mice and S334ter-3 rats were produced by previously published methods. VPA (200 mg/kg) or a placebo was administered daily (i.p.) to P23H mice, littermate controls, or C57/B6 mice every other day for two weeks. The mice were dark-adapted overnight and their eyes were then harvested in dim red light. The total folded rhodopsin was purified from each eye and quantified by UV/visible spectroscopy using our previously published methods. Separately, in the S334ter rats, either VPA (300 mg/ml) or a placebo was administered via i.p. daily, starting at PD 9. Eyes were collected at PD 21, embedded in an Epon/Araldite mixture, and sectioned at 1 µm thickness to display the entire retina along the vertical meridian. Retinal sections were examined by light microscopy and evaluated independently by three observers.

Results: : When compared to the retinas receiving a placebo, the P23H mice treated with VPA had an approximately 30-40% increase in the amounts of folded rhodopsin, which was statistically significant. There was no substantial effect of VPA on the littermate controls or the C57/B6 mice. In the retinas of the S334ter rats treated with VPA, the outer nuclear layer (ONL) had 2-3 rows of photoreceptor nuclei in the superior retina. In contrast, animals treated with PBS had only 1 row of nuclei in the ONL of the same retinal region. Separate quantitative data showed that the ONL thickness in treated animals was significantly higher than the controls.

Conclusions: : Systemically delivered VPA in P23H mice resulted in increased folded rhodopsin levels and in modest but significant preservation of photoreceptors in the S334ter-3 rats.

Keywords: protective mechanisms • retinal degenerations: cell biology • retinitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×